Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30545253 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRHSD17B10CYP3A4HPGD | |
| SCHEMBL29428696 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRHSD17B10CYP3A4HPGD | |
| SCHEMBL26011162 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRHSD17B10CYP3A4HPGD | |
| SCHEMBL26011160 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRHSD17B10CYP3A4HPGD | |
| SCHEMBL23212496 | 0.84 | ALDH1A1 (0.41) | ALDH1A1TSHRHSD17B10CYP3A4HPGD | |
| SCHEMBL30302288 | 0.84 | ALDH1A1 (0.41) | ALDH1A1TSHRHSD17B10CYP3A4HPGD | |
| SCHEMBL588459 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TSHRHSD17B10CYP3A4HPGD | |
| SCHEMBL1187339 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TSHRHSD17B10CYP3A4HPGD | |
| SCHEMBL29374267 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TSHRHSD17B10CYP3A4HPGD | |
| SCHEMBL29353343 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TSHRHSD17B10CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907387-B | Pyrimido pyrrole KRAS inhibitor and preparation method and application thereof | 中山大学 | 2023-11-10 | — | — | CN | claimed |
| CN-114907387-A | Pyrimidopyrrole KRAS inhibitor and preparation method and application thereof | 中山大学 | 2022-08-16 | — | — | CN | claimed |
| EP-3339302-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-06-27 | — | — | EP | claimed |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2017-07-06 | — | — | US | claimed |
| EP-2944633-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2015-11-18 | — | — | EP | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260035339-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | ATRANSEN PHARMA LTD (JP) | 2026-02-05 | — | — | US | disclosed |
| US-20260035389-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12497396-B2 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| EP-4031542-B1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12421253-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-7186469-B2 | Bathophenanthroline compound and EL device | SONY CORPORATION (JP) | 2007-03-06 | — | — | US | disclosed |
| US-7186469-B2 | Bathophenanthroline compound and EL device | SONY CORPORATION (JP) | 2007-03-06 | — | — | US | disclosed |
| US-6972334-B1 | Bathophenathroline compound and process for preparing same | SONY CORPORATION (JP) | 2005-12-06 | — | — | US | disclosed |
| US-20050154208-A1 | Device utilizing bathophenanthroline compound and process for preparing same | SHIBANUMA TETSUO (JP) | 2005-07-14 | — | — | US | disclosed |
| US-20050073641-A1 | Bathophenanthroline compound and process for preparing same | SHIBANUMA TETSUO (JP) | 2005-04-07 | — | — | US | disclosed |
| US-20040265626-A1 | Optical recording medium | JOLED INC. (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1097980-A2 | Bathophenanthroline compound and process for preparing same | SONY CORPORATION (JP) | 2001-05-09 | — | — | EP | disclosed |
| US-4246268-A | ANTIPSYCHOTICS, TRANQUILIZERS, NEUROLEPTICS COMPOUNDS AND NOVEL INTERMEDIATES | RICHARDSON-MERRELL INC. (US) | 1981-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050073641-A1 | Bathophenanthroline compound and process for preparing same | BZW1, BZW2, RPAP1 | ALDH1A1 1479/4885TSHR 2539/4885HSD17B10 757/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | ALDH1A1 1816/4885TSHR 4213/4885HSD17B10 3711/4885 |
| US-12421253-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3283/4885TSHR 3021/4885HSD17B10 4665/4885 |
| US-20260035339-A1 | TETRAHYDRONAPHTHALENE DERIVATIVE | LATS1, LATS2, BCAT1 | ALDH1A1 1267/4885TSHR 3063/4885HSD17B10 548/4885 |
| US-20050154208-A1 | Device utilizing bathophenanthroline compound and process for preparing same | BZW1, BZW2, AHR | ALDH1A1 1377/4885TSHR 2570/4885HSD17B10 380/4885 |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | HPRT1, XDH, NUDT1 | ALDH1A1 423/4885TSHR 3577/4885HSD17B10 636/4885 |
| US-12497396-B2 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | KRAS, NRAS, GNAQ | ALDH1A1 2233/4885TSHR 4349/4885HSD17B10 4101/4885 |
| US-20260035389-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 2072/4885TSHR 3060/4885HSD17B10 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.